Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.

Among frail older adults with OAB, mirabegron use was associated with higher costs and potential improvements in treatment-taking behaviors, particularly with respect to treatment adherence, versus those initiating antimuscarinics.